Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
The drugmaker says the therapeutic approach has a narrow treatment potential.
Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.
Roche also announced first-quarter sales shrank 1%.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
New data from the International Liver Congress in London this past weekend showed strong efficacy for Gilead's Sovaldi and AbbVie's combo regimen when paired with ribavirin.
Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.
A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.
Politico calls her departure an "everybody wins" situation.
New leaders include Pfizer's Ian Read, Merck's Kenneth Frazier and Biogen Idec's George Scangos.
Physicians Desk Reference is on a mission to expand its image beyond just being that heavy book doctors consult for information
Complete data sets have prompted researchers to say Tamilflu and Relenza fail at their key reason for being: preventing flu pandemics.
Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
CDM, the Omnicom network of healthcare agencies, named Josh Prince, previously the group's chief creative officer, to president. He replaces Carol DiSanto.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
23andMe cofounder Linda Avey is taking crowdsourced patient experiences to the web with a soft July launch of a platform called Curious.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
The regulator has put off the inhaled insulin's PDUFA date by three months.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
The drugmaker said today that FDA has granted the company a Breakthrough Therapy designation and a priority review for its sofosbuvir/ledipasvir combo.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The announcement will create the fifth largest generics drug maker, reports Reuters.
The Swiss drugmaker has scooped up Oryzon's experimental acute myeloid leukemia treatment and private Massachusetts diagnostics firm IQuum.
WSJ's sources say allegations of misconduct are similar to those leveled against the company in China.
Almost a week after announcing Baxter was going to break into two divisions, the Illinois company is already expanding.
Kaiser Permanente is swallowing the cost of Gilead's hepatitis C treatment Sovaldi, but is angry about the $84,000 cost.
The top 34 UK drug companies paid medical professionals around $64 million last year, for services that included speeches, medical study participation and third-party meeting sponsorships.
GlaxoSmithKline got some unwelcome attention from the FDA inspectors: a March 27 warning letter about unacceptable manufacturing and communications at a Cork, Ireland, manufacturing site where it found contamination issues.
A recent study shows that generic fill data, often used to promote the cost-savings associated with generic drugs, may hide the impact some health insurance plans have on patient medication use.
The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.
The GSK-Pfizer-Shionogi joint venture said it will add HIV med Tivicay to a United Nations patent pool, cutting its price for developing countries and granting access for generics firms.
The drugmaker is ceasing a trial called MAGRIT after it was unable to identify patients who could benefit from MAGE-A3.
Praised for helping navigate the shift by advertisers into digital, media vet Kim Kadlec is leaving pharma for a new role at AOL.
MannKind's inhalable insulin, a pipeline contender for 14 years, scored a near unanimous vote from an FDA advisory committee yesterday.
The FDA has issued draft guidance that funds FDA inspection of some drug compounders.
The Israel-based drugmaker will try to extend the MS treatment's patent life until September 2015.
The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.
A court granted Lilly six more years of patent protection for the almost $3-billion-dollar-a-year cancer drug.
At a hearing today, Public Citizen and the generics industry are sounding off on an FDA proposal that would allow generics firms to update labels, regardless of whether the brand has or hasn't.
Apollo EndoSurgery has tapped W2O Group as its agency of record for its LAP-BAND weight reduction system.
Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.
The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.
The FDA has approved a 24-hour version of Pfizer's heartburn medication.
The Carlyle Group has picked up Johnson & Johnson's Ortho Diagnostics for $4B.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
The Bay State is saying no to the controversial prescription painkiller.
Phase-I tests show Novartis's ceritinib works on Xalkori-resistant patients.
The company, which expects a 9% to 10% sales jump in 2014, says it will split into two independent companies by the middle of next year.
Pfizer's investigational LDL-C lowering treatment bococizumab reduced LDL cholesterol in patients also taking statins.
Tampering concerns prompted the company's action.
Takeda's DPP-4 diabetes treatment, Nesina, showed no effect on CV mortality rates or hospitalization for heart failure in sub-analyses.
With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.
The March 31 deadline for health insurance is not the be-all-and-end-all, while a survey found that 50% of the uninsured intend to stay that way.
The regulator disputes findings that generic heart drugs made abroad were contaminated.
The three-year collaboration includes $1.5 million for chronic kidney disease research.
The company said it wants to wait for more data to come in.
A study by consulting firm Accenture shows that patients not only expect digital outreach, but that their desire to be engaged is consistently being ignored.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
Novartis's acute heart failure drug was not recommended for approval, according to an FDA advisory panel.
Flagging sales and patent expirations are keeping Lilly's pay rates static. AbbVie's CEO's paycheck reflects his new digs.
The professional association says it's necessary, because high prices do not indicate impact.
The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.
Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.
The IPO could be the third largest of the year.
The FDA's approval makes Genentech's drug the first biologic for chronic hives.
The new indication would mean Tresiba and Victoza could be prescribed in tandem.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.
AbbVie's "Perspectives—Art, Inflammation and Me," an exhibit centered around inflammatory diseases, looks to offer patient perspective through an artistic medium.
Longtime industry critic, Congressmen Henry Waxman penned a note to Gilead CEO over the "extraordinarily high cost," of its recently approved HCV treatment Sovaldi.
Celgene is looking to market the $22,500-a-year-drug as a pre-biologic, which means jumping ahead of rivals like Enbrel and Humira.
The Committee for Medicinal Products for Human Use endorses the SGLT2 inhibitor. The FDA refused to approve the drug earlier this month because of manufacturing issues.
Chandler Chicco Agency and Mylan Specialty's "Raise Your Hand for Anaphylaxis Awareness" program is named Healthcare Campaign of the Year at PRWeek Awards
The drugmaker halted Phase III trials of a three-month medication based on good efficacy feedback.
The company says it will continue to test its MAGE-A3 cancer drug among a subset of non-small cell lung cancer patients and among melanoma patients.
The drugmaker's CEO tells Reuters it is in a good position to weather troubles in India's generics industry.
The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.
A Wall Street Journal blog post claims that a recent US district court judge's opinion regarding patent settlements may call into question the very definition of "reverse settlements."
The 2013 guidelines add 12.8 potential statin users to the pool, but this growth does not necessarily mean still-experimental PCSK9s will be able to capitalize on the greater patient population.
Biogen Idec announced yesterday that FDA will extend Plegridy's review data for three months; regulators did not request additional studies be done, the drugmaker said.
Researchers find that Canada has been a significant contributor to Zetia sales.
Arena and Eisai are testing Belviq with appetite suppressant phentermine.
Astellas and Medivation have applied for a pre-chemo indication for the cancer drug.
The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.
A recent Medscape survey found that under-40s were more likely to work for a healthcare organization than were their older colleagues, trading autonomy for work-life balance and income predictability.
The company is suing Torrent Pharmaceuticals, which wants to market a drug before the patent lapses in 2019.
A working group set out parameters for what counts as a meaningful outcome for pancreatic, breast, lung and colon cancer clinical trials.
Researchers say saturated fat may not cause heart disease, but critics say the study is too narrow.
The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.
The FDA approved the blood drug to prevent deep vein thrombosis and pulmonary embolism among hip- and knee-replacement patients. The approval means BMS and Pfizer may encroach upon the territory of J&J's Xarelto.
The Thousand Oaks, Calif. company says its cholesterol-lowering antibody hit its clinical trial endpoint among rare disease patients.
The drugmaker revealed part 2 of its plan not to pay doctors to speak on GSK's behalf: it will make them employees.
West Virginia's Joe Manchin has sponsored a bill to push pain medication Zohydro off the FDA's approval list.